Hendley & Co. Inc. Has $5.37 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Hendley & Co. Inc. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 56.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,040 shares of the company's stock after acquiring an additional 26,260 shares during the period. AstraZeneca makes up about 1.9% of Hendley & Co. Inc.'s investment portfolio, making the stock its 17th largest holding. Hendley & Co. Inc.'s holdings in AstraZeneca were worth $5,368,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in AZN. Banque Transatlantique SA acquired a new stake in AstraZeneca in the fourth quarter valued at $26,000. Confluence Investment Management LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth about $27,000. Mascagni Wealth Management Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter worth about $29,000. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth about $29,000. Finally, Highline Wealth Partners LLC lifted its stake in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after buying an additional 340 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

Analyst Ratings Changes

Separately, BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $85.00.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded up $0.80 on Wednesday, reaching $70.82. 3,662,688 shares of the stock were exchanged, compared to its average volume of 5,260,237. The firm's 50 day moving average is $70.74 and its 200-day moving average is $70.71. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The firm has a market cap of $219.64 billion, a PE ratio of 28.44, a P/E/G ratio of 1.28 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.06 EPS. As a group, analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.